Vertex Pharmaceuticals Inc 

VRTX:NASDAQ

LastChange / % ChangeDividend YieldVolume
39.42 0.8700   2.26%0.00%3,006,503

Market data is delayed by at least 20 minutes.

Exclusive Features

When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes.

For full analysis details, Log In with Scottrade or you can:
  •  
    Advanced Charts

  •  
    Embed Chart

    Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

  • 1 Day
  • 5 Day
  • 6 Mo
  • 1 Yr
  • 5 Yr
 
 
 

Latest News Headlines for Vertex Pharmaceuticals Inc

Uptrend Spotted in Shares of Vertex Pharmaceuticals (VRTX)
2 days 7 hours 54 minutes ago - Comtex SmarTrend(R)
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on December 20, 2010 at $35.52. In approximately 4 weeks, Vertex Pharmaceuticals has returned 11% as of today's recent price of $39.42.
Shares of MannKind Rank the Highest in terms of Relative Performance in the Biotechnology Industry (MNKD, VRTX, AMLN, THRX, NPSP)
3 days 15 hours 29 minutes ago - Comtex SmarTrend(R)
Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the potential to outperform.
Vertex Pharmaceuticals (VRTX) Showing Bullish Technicals But Could Fall Through $35.72 Support
5 days 11 hours 55 minutes ago - FreshBrewedMedia
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) closed Tuesday's trading session at $36.79. In the past year, the stock has hit a 52-week low of $31.25 and 52-week high of $43.94. Vertex Pharmaceuticals stock has been showing support around $35.72 and resistance in the $38.38 range. Technical indicators for the stock are Bullish and S&P; gives VRTX a very positive 5 STARS (out of 5) strong buy rating. For a hedged play on this stock, look at the Apr '11 $36.00 covered call for a net debit in the $33.59 area. That is also the break-even stock price for this trade. This covered call has a duration of 94 days, provides 8.70% downside protection and an assigned return rate of 7.17% for an annualized return rate of 27.86% (for comparison purposes only). A lower-cost hedged play for this stock would use a longer term call option in place of the covered call stock purchase. To use this strategy look at going long the VRTX Jan '12 $25.00 call and selling the Apr '11 $36.00 call for a total debit of $10.45. The trade has a lifespan of 94 days and would provide 3.64% downside protection and an assigned return rate of 5.26% for an annualized return rate of 20% (for comparison purposes only). Vertex Pharmaceuticals does not pay dividends at this time.
View more recent headlines
 
 
 
 
 
 
More Filings

Latest Annual and Quarterly SEC Filings

10-K
February 19, 2010
This report contains detailed information about the company's business finances and management.
10-Q
October 28, 2010
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
 
 
 
Company Background
Vertex Pharmaceuticals Incorporated (Vertex) is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. Telaprevir, the Company's lead drug candidate, is an oral hepatitis C protease inhibitor and a new class of antiviral treatments in clinical development that target hepatitis C virus (HCV), infection. Telaprevir is being evaluated in a registration program focused on treatment-naïve and treatment-failure patients with genotype 1 HCV infection. VX-770, the lead drug candidate in its cystic fibrosis (CF), program is being evaluated in a registration program that focuses on patients with CF who have the G551D mutation in the gene responsible for CF. Vertex is conducting a number of Phase IIa clinical trials of its earlier-stage drug candidates. On March 12, 2009, Vertex acquired ViroChem Pharma Inc. (ViroChem).
Bid/Size
-- / --
Ask/Size
-- / --
Price Open
38.56
Previous Close
38.55
Day High
39.42
Day Low
38.32
52wk High/Date
43.94 / 3/16/2010
52wk Low/Date
31.25 / 7/1/2010
Beta
0.55
Market Capitalization
8B
Shares Outstanding
203M
Volatility Avg
29.79
Avg Vol(10 day)
2M
P/E Ratio
NM
EPS (TTM)
-4
Annualized Rate
-- / --
Yield
0.00%
Dividend Announcement
--
Ex-Date
--
Date of Record
--
Payable
0.00 - --
Payable Date
--
Last Trade as of 1/14/2011 4:00 PM ET

Exclusive Content

When you open an account with Scottrade, you will get premium content on the News & Content page, including:

  • Standard & Poor's News and Commentary
  • Dow Jones News
  • Briefing News and Commentary
  • Market Edge On the Edge Commentary
For full analysis details, Log In with Scottrade or you can:
 
 
 

VRTX Vertex Pharmaceuticals Inc vs. Peers

Peers 
VRTX
Vertex Pharmaceuticals Inc
12.53%
MRK
Merck & Co., Inc.
-5.02%
PFE
Pfizer Inc.
4.74%
AMGN
Amgen, Inc.
2.91%
JNJ
Johnson & Johnson
1.13%
VRTX
Vertex Pharmaceuticals Inc
0.00%
MRK
Merck & Co., Inc.
4.44%
PFE
Pfizer Inc.
4.36%
AMGN
Amgen, Inc.
--
JNJ
Johnson & Johnson
3.45%
VRTX
Vertex Pharmaceuticals Inc
2.26%
MRK
Merck & Co., Inc.
-1.33%
PFE
Pfizer Inc.
0.66%
AMGN
Amgen, Inc.
0.32%
JNJ
Johnson & Johnson
-0.57%
Compare these stocks
 
 
 
© 2011 Scottrade

Brokerage Products and Services offered by Scottrade, Inc. - Member FINRA and SIPC

Online market and limit stock trades are just $7 for stocks priced $1 and above.

Any specific securities, or types of securities, used as examples are for demonstration purposes only. No information on this Web site should be considered a recommendation or None of the information provided should be considered a recommendation or solicitation to invest in, or liquidate, a particular security or type of security.

Investors should consider the investment objectives, risks, and charges and expenses of a mutual fund carefully before investing. A mutual fund's prospectus contains this and other information about the mutual fund. Prospectuses are available through our trading site or through a Scottrade Branch Office. The prospectus should be read carefully before investing. No transaction fee (NTF) funds are subject to the terms and conditions of the NTF funds program. Scottrade is compensated by the funds participating in the NTF program through recordkeeping, shareholder, or SEC 12b-1 fees.

Investors should consider the investment objectives, charges, expense, and unique risk profile of an Exchange Traded Fund (ETF) carefully before investing. Leveraged and Inverse ETFs may not be suitable for long-term investors and may increase exposure to volatility through the use of leverage, short sales of securities, derivatives and other complex investment strategies. A prospectus contains this and other information about the ETF and should be obtained from the issuer. The prospectus should be read carefully before investing.

Margin trading involves interest charges and risks, including the potential to lose more than deposited, or the need to deposit additional collateral in a falling market. Margin Disclosure Statement (PDF) is available for download, or it is available at one of our branch offices. It contains information on our lending policies, interest charges, and the risks associated with margin accounts.

Options involve risk and are not suitable for all investors. Detailed information on our policies and the risks associated with options can be found in the Scottrade Options Application and Agreement, Brokerage Account Agreement, and by downloading the Characteristics and Risks of Standardized Options and Supplements (PDF) from The Options Clearing Corporation, or by requesting a copy from your local branch office. Supporting documentation for any claims will be supplied upon request.

Market volatility, volume, and system availability may impact account access and trade execution.

Testimonials may not be representative of the experience of other clients and are no guarantee of future performance or success.